With over 10,000 rare diseases affecting patients worldwide, approximately 70% of these conditions manifest in childhood.
Yet only 5% have an approved therapy, and none offers a cure, leaving a significant unmet medical need.
Due to the limited number of patients for large-scale trials in rare paediatric diseases, N-of-1 clinical trials provide an innovative, personalised approach to treatment development.
Check out the rest of the feature here
